Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-TOLE3: XEN1101 adjunctive therapy in focal-onset seizures
2022-502281-25-00Phase 3Authorised
- Sponsor
- Xenon Pharmaceuticals
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in Focal Onset Epilepsy and Focal onset seizure comparing XEN1101 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: 50% responder rate in monthly focal seizure frequency. Planned start Sep 2023; status: authorised.
02
Drugs
azetukalner
03
Conditions
Focal Onset EpilepsyFocal onset seizure
Beyond the preview
Go deeper on 2022-502281-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502281-25-00.